- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05099601
Silymarin Cream Versus Combined Silymarin Cream and Microneedling in Treatment of Melasma
Topical Silymarin Versus Combined Topical Silymarin and Microneedling in Treatment of Melasma: Split Face Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Many studies examined multiple treatment options for melasma, but none of them is completely satisfactory with recurrence in most cases.
Silymarin (SM) is a standardized extract from Silybum marianum seeds, is traditionally used as a hepatoprotective agent for its potent regenerative properties. Lately, SM is utilized in dermatological and cosmetic preparations for its antioxidant effect, anti-inflammatory and immunomodulatory properties.
Silibinin, the main component of silymarin, has been found to have antioxidant properties. It decreases the hazardous effects of solar ultraviolet radiation and significantly prevents melanin production in a dose-dependent manner without effect on cell viability.
Skin microneedling, or percutaneous collagen induction by needles, is a minimally invasive procedure that uses short fine needles to puncture the skin and stimulates fibroblast proliferation, release of growth factors and collagen production.
Long-term improvement of melasma after microneedling was reported , however, the exact mechanism that promotes skin lightening is not known.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sahar A Ismail, Professor
- Phone Number: +201008899446
- Email: Saharsotohy@yahoo.com
Study Contact Backup
- Name: Rofaida R Shehata, PHD
- Phone Number: +201006897580
- Email: rofaida.refaat@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-50 years old.
- Pattern of melasma: Bilateral symmetrical facial melasma of any pattern.
- Fitzpatrick skin phototypes: Types III, IV and V
Exclusion Criteria:
- Pregnancy and lactation.
- Patients taking oral contraceptive pills, hormonal replacement therapy or treatment for chronic illness at the time of the study or during the past 6 months.
- Coexistance of diseases associated with hyperpigmentation such as Addison disease.
- Scarring and keloid tendency, active skin infections as active HSV.
- Previous history of post inflammatory hyperpigmentation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Silymarin alone versus silymarin and microneedling
There will be one group of patients.
Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.
|
The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
Patients will be subjected to microneedling sessions on one side of the face.
Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen.
Sessions will be done by well trained physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
compare between the efficacy of topical silymarin alone and its combination with microneedling in treatment of melasma.
Time Frame: 3 months
|
Scoring of the patients according to modified Melasma Area and Severity Index (mMASI) score before and after treatment.
|
3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A Comprehensive Review. Dermatol Surg. 2017 Mar;43(3):321-339. doi: 10.1097/DSS.0000000000000924.
- Nofal A, Ibrahim AM, Nofal E, Gamal N, Osman S. Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study. J Cosmet Dermatol. 2019 Feb;18(1):263-270. doi: 10.1111/jocd.12769. Epub 2018 Aug 26.
- Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013 Feb;27(2):151-6. doi: 10.1111/j.1468-3083.2011.04430.x. Epub 2012 Jan 3.
- Vaid M, Katiyar SK. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol. 2010 May;36(5):1053-60. doi: 10.3892/ijo_00000586.
- Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003 Sep;149(3):572-7. doi: 10.1046/j.1365-2133.2003.05419.x.
- Choo SJ, Ryoo IJ, Kim YH, Xu GH, Kim WG, Kim KH, Moon SJ, Son ED, Bae K, Yoo ID. Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol. 2009 May;61(5):663-7. doi: 10.1211/jpp/61.05.0016.
- Cohen BE, Elbuluk N. Microneedling in skin of color: A review of uses and efficacy. J Am Acad Dermatol. 2016 Feb;74(2):348-55. doi: 10.1016/j.jaad.2015.09.024.
- Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014 Sep-Oct;89(5):771-82. doi: 10.1590/abd1806-4841.20143063.
- Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994 Jun;130(6):727-33.
- Kren V, Walterova D. Silybin and silymarin--new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Jun;149(1):29-41.
- Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, Nordlund JJ, Rendon M, Taylor S, Gottschalk RW, Agim NG, Ortonne JP. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011 Jan;64(1):78-83, 83.e1-2. doi: 10.1016/j.jaad.2009.10.051. Epub 2010 Apr 15.
- Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol. 2007 Sep;6(3):195-202. doi: 10.1111/j.1473-2165.2007.00321.x.
- Tran JM, Chan AW (2012) Quick diagnosis: melasma. University of Toronto Med J 89: 143-145.
- Wu DC, Fitzpatrick RE, Goldman MP. Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma. J Clin Aesthet Dermatol. 2016 Feb;9(2):48-57.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melasma
-
Mesoestetic Pharma Group S.L.Completed
-
ConBio, a Cynosure CompanyCompleted
-
University of Nove de JulhoRecruiting
-
Jinnah Postgraduate Medical CentreActive, not recruiting
-
China Medical University HospitalCompleted
-
VIST - Faculty of Applied SciencesActive, not recruiting
-
China Medical University HospitalApollo Medical Optics, LtdCompleted
-
Combined Military Hospital AbbottabadCompleted
-
Northwestern UniversityCompleted
-
Centre Hospitalier Universitaire de NiceCompleted
Clinical Trials on Silymarin
-
Vanderbilt UniversityWithdrawn
-
Isfahan University of Medical SciencesMadaus IncUnknownIron Overload | Beta-thalassemia MajorIran, Islamic Republic of
-
University of Sao Paulo General HospitalUniversity of Sao PauloCompletedHealthy | Inflammatory Bowel Diseases | Insulin Resistance | Overweight and ObesityBrazil
-
Madaus IncUniversity of Pennsylvania; Beth Israel Deaconess Medical Center; University... and other collaboratorsCompletedNon-alcoholic SteatohepatitisUnited States
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedLeukemia | Drug/Agent Toxicity by Tissue/OrganUnited States, Canada
-
Shiraz University of Medical SciencesCompletedImmune AbnormalitiesIran, Islamic Republic of
-
Ramathibodi HospitalCompleted
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)CompletedHepatitis C, Chronic
-
Tanta UniversityNot yet recruiting